Comparative efficacy and safety of pyrotinib plus trastuzumab versus trastuzumab plus pertuzumab and trastuzumab monotherapy in neoadjuvant treatment of HER2-positive breast cancer: A systematic review and meta-analysis
Cancer Treatment Reviews · 2025-03 · 134 · 102901
DOI: 10.1016/j.ctrv.2025.102901 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Cancer Treatment Reviews, 2025-03. Verfasst von Ye Yuan und 5 weiteren Autor:innen. Beteiligte Einrichtung: Sichuan Integrative Medicine Hospital, China. Electronic address: yuanyeah0811@163.com. Hauptthemen laut MEDLINE: Breast Neoplasms, Trastuzumab, Antineoplastic Combined Chemotherapy Protocols, Aminoquinolines. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Sichuan Integrative Medicine Hospital, China. Electronic address: yuanyeah0811@163.com.
- Chengdu Anticancer Bioscience, China.
- Sichuan Integrative Medicine Hospital, China.
- Sichuan Integrative Medicine Hospital, China. Electronic address: 26011707@qq.com.
Zitieren
APA
Yuan, Y., Liu, X., Xu, G., Zhang, J., Chen, L., & Long, X. (2025). Comparative efficacy and safety of pyrotinib plus trastuzumab versus trastuzumab plus pertuzumab and trastuzumab monotherapy in neoadjuvant treatment of HER2-positive breast cancer: A systematic review and meta-analysis. Cancer Treatment Reviews, 134, 102901. https://doi.org/10.1016/j.ctrv.2025.102901
Vancouver
Yuan Y, Liu X, Xu G, Zhang J, Chen L, Long X. Comparative efficacy and safety of pyrotinib plus trastuzumab versus trastuzumab plus pertuzumab and trastuzumab monotherapy in neoadjuvant treatment of HER2-positive breast cancer: A systematic review and meta-analysis. Cancer Treatment Reviews. 2025;134:102901. doi:10.1016/j.ctrv.2025.102901
BibTeX
@article{Yuan2025,
author = {Yuan, Ye and Liu, Xumei and Xu, Gaifeng and Zhang, Ji and Chen, Li and Long, Xin},
title = {Comparative efficacy and safety of pyrotinib plus trastuzumab versus trastuzumab plus pertuzumab and trastuzumab monotherapy in neoadjuvant treatment of HER2-positive breast cancer: A systematic review and meta-analysis},
journal = {Cancer Treatment Reviews},
year = {2025},
volume = {134},
pages = {102901},
doi = {10.1016/j.ctrv.2025.102901}
}
EUVIMED